drugset / Trial / NCT03489304

Zaleplon in HIV Patients With Depression

NCT03489304

Phase 2 Completed 20 enrolled University of Pennsylvania
NaSingle-groupOpen-labelTreatment

Summary

In HIV positive patients with sleep onset insomnia and receiving pharmacologic treatment for comorbid depression, the proposed study aims to evaluate the impact of zaleplon on sleep measures determined by insomnia severity index (ISI) and Epworth sleepiness scale (ESS).

Timeline

Start
2014-04-03
Primary completion
2015-02-04
Completion
2015-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Zaleplon Small molecule 5 mg
Subject Zaleplon Small molecule 10 mg